An optical fiber balloon catheter

Abstract

The present invention discloses an optical fiber balloon catheter, which relates to the technical field of medical devices. The optical fiber balloon catheter includes a catheter body, a balloon, and a flow retardation component; the balloon is arranged at the distal end of the catheter body, and a drug is disposed on the surface of the balloon; at least during the process of delivering the balloon to the target site, the flow retardation component is located on the receiving side of the balloon facing the fluid impact, and the flow retardation component is used to slow down the scouring of the fluid on the drug on the surface of the balloon during this process; wherein, when the optical fiber balloon catheter moves in the reverse direction relative to the fluid, the receiving side is the distal side of the balloon; when the optical fiber balloon catheter moves in the same direction relative to the fluid, the receiving side is the proximal side of the balloon. The present invention improves the structure of the optical fiber balloon catheter, slows down the scouring of the fluid on the balloon during the delivery process, and effectively reduces the loss of the photosensitizer on the surface of the balloon during transportation.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and particularly to an optical fiber balloon catheter. Background Art

[0002] Among many cardiovascular diseases, vascular stenosis lesions are relatively serious. Vascular interventional therapy is an important treatment method for revascularization of vascular stenosis lesions.

[0003] For intravascular stenosis lesions, balloon dilation or stent implantation is usually used for treatment, but both methods have their own deficiencies: after balloon dilation, the vascular endothelium of the dilated arterial segment is damaged and elastic fibers are broken, resulting in thrombosis and intimal hyperplasia; the inflation time of the balloon during use is short and it lacks long-term supporting force, resulting in elastic recoil and remodeling of the tube wall; long-term placement of a vascular stent will also cause a body proliferation reaction as a foreign body, leading to restenosis within the vascular stent.

[0004] In response to the above problems, a natural vascular stent has emerged. A photosensitizer is coated on the balloon. After the balloon is dilated, the photosensitizer is released onto the inner wall of the blood vessel, and light with a specific wavelength (400 - 500 nm) is emitted through an optical fiber to activate the photosensitizer, triggering the formation of covalent cross-links of amino acids on the inner wall of the blood vessel, which has a supporting effect on the blood vessel, thereby avoiding the problem of blood vessel retraction.

[0005] In the prior art, for example, a patent with publication number CN119034087A discloses a drug balloon delivery catheter, including a catheter body. The catheter body is provided with a balloon body and a blocking balloon. Drugs are evenly distributed on the surface of the balloon body; the balloon body has an olive-like structure. After the balloon body reaches the target treatment area, the filling holes opened on the catheter body inject a filling liquid into the balloon body to make the balloon body expand. After the balloon body expands, it fully adheres to the target inner wall; before the balloon body expands, the blocking balloon is filled to block the blood flow in the blood vessel. However, the prior art only considers forming a completely blocked area during the short drug release period in the target treatment area to block the scouring of the blood flow on the balloon body. However, during the process of delivering the balloon to the diseased tissue, due to the large blood flow rate and flow volume, a part of the photosensitizer on the surface of the balloon will be lost due to the scouring of the blood flow, so that only part of the photosensitizer can reach the diseased position. Summary of the Invention

[0006] The main object of the present invention is to provide an optical fiber balloon catheter, aiming to slow down the scouring of the fluid on its balloon during the delivery process of the optical fiber balloon catheter and reduce the loss of the drug on the surface of the balloon during transportation.

[0007] To achieve the above object, the present invention provides an optical fiber balloon catheter, including:

[0008] Catheter body;

[0009] A balloon, provided at the distal end of the catheter body, with a drug disposed on the surface of the balloon; and

[0010] A flow retardation member, at least during the process of delivering the balloon to the target site, the flow retardation member is located on the receiving side of the balloon facing the fluid impact, and the flow retardation member is used to slow down the erosion of the fluid on the drug on the surface of the balloon during this process;

[0011] Wherein, when the fiber balloon catheter moves reversely relative to the fluid, the receiving side is the distal side of the balloon; when the fiber balloon catheter moves in the same direction as the fluid, the receiving side is the proximal side of the balloon.

[0012] Optionally, define the size of the flow retardation member in the radial direction of the catheter body when it is in the working state as a, and define the size of the balloon in the radial direction of the catheter body when it is in the folded state as b, then the following relational expression is satisfied:

[0013] b ≤ a < c;

[0014] In the formula, c is the inner diameter of the human blood vessel.

[0015] Optionally, the flow retardation member is an inflatable body, and the catheter body is provided with a first channel and a second channel both for introducing liquid. The balloon is communicated with the first channel, and the inflatable body is provided at the distal end of the catheter body and communicated with the second channel.

[0016] Optionally, the projection of the inflatable body in the radial direction of the catheter body is circular, oval, peanut-shaped, "T"-shaped, umbrella-shaped or conical.

[0017] Optionally, the flow retardation member is a foldable structure, and the catheter body is provided with a third channel for a slow-flow guide wire to pass through. The third channel has an outlet on the distal side of the balloon. The foldable structure is delivered to the outside of the outlet of the third channel through the slow-flow guide wire and automatically unfolds after leaving the outlet of the third channel.

[0018] Optionally, the foldable structure is a metal braided wire basket, a crocheted wire basket or a metal stent wrapped with a polymer filter membrane basket.

[0019] Optionally, the size of the foldable structure in the radial direction of the catheter body when it is in the folded state is smaller than the size of the third channel in the radial direction of the catheter body.

[0020] Optionally, the flow retardation member includes a folding frame and a flow-blocking film wrapped on the folding frame, and the flow-blocking film is provided with a flow-blocking surface on the receiving side facing the fluid impact.

[0021] Optionally, the catheter body is further provided with a fourth channel for the fiber optic to pass through. The fourth channel communicates with the balloon, and the proximal end of the fiber optic is connected to an external laser generator; and / or

[0022] The fiber optic balloon catheter further includes a catheter seat disposed at the proximal end of the catheter body. The catheter seat is provided with a plurality of interfaces or inlets that communicate with the inner cavity of the catheter body one by one.

[0023] Optionally, the drug includes a photosensitizer, and the photosensitizer is naphthalimide dimer and its derivatives; the drug further includes a drug for inhibiting vascular restenosis, and the drug for inhibiting vascular restenosis is a macrolide immunosuppressant, a macrolide antibiotic, rapamycin, a structural derivative and a functional analogue of rapamycin, everolimus, a structural derivative and a functional analogue of everolimus, paclitaxel, taxanes, zotarolimus, sirolimus, biolimus, tacrolimus or temsirolimus or temsirolimus compound.

[0024] In the technical solution of the present invention, the fiber optic balloon catheter includes a catheter body, a balloon and a flow retarder; the balloon is disposed at the distal end of the catheter body, and a drug is provided on the surface of the balloon; at least during the process of delivering the balloon to the target site, the flow retarder is located on the receiving side of the balloon facing the fluid impact, and the flow retarder is used to slow down the scouring of the fluid on the drug on the surface of the balloon during this process; wherein, when the fiber optic balloon catheter moves reversely relative to the fluid, the receiving side is the distal side of the balloon; when the fiber optic balloon catheter moves in the same direction as the fluid, the receiving side is the proximal side of the balloon. It can be understood that the present invention improves the structure of the fiber optic balloon catheter, slows down the scouring of the fluid on the balloon during the delivery process, and effectively reduces the loss of the drug on the surface of the balloon during transportation. Description of the Drawings

[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for use in the description of the embodiments or the prior art. Obviously, the following drawings are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on the structures shown in these drawings.

[0026] Figure 1 It is a schematic diagram of the structure and its application of Scheme 1 of an embodiment of the fiber optic balloon catheter of the present invention;

[0027] Figure 2 It is a schematic diagram of the structure and its application of Scheme 2 of an embodiment of the fiber optic balloon catheter of the present invention;

[0028] Figure 3Schematic diagram of the structure and its application of another embodiment of the fiber optic balloon catheter of the present invention;

[0029] Figure 4 Schematic diagram of the structure and its application of yet another embodiment of the fiber optic balloon catheter of the present invention.

[0030] Explanation of the reference numerals in the drawings:

[0031] Ve, blood vessel; 10, catheter body; 20, balloon; 31, inflatable body; 32, foldable structure; 321, flow retardation wire; 331, folding frame; 332, flow blocking film; 333, receiving sleeve; 40, optical fiber; 50, catheter hub; 50a, balloon inflation port; 50b, guide wire outlet; 50c, optical fiber inlet; 50d, inflatable body inflation port; 50e, foldable structure inlet.

[0032] The realization, functional features and advantages of the object of the present invention will be further described in conjunction with the embodiments with reference to the accompanying drawings. Detailed implementation manners

[0033] Next, the technical solutions in the embodiments of the present invention will be clearly and completely described in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.

[0034] It should be noted that all directional indications (such as up, down, left, right, front, back,...) in the embodiments of the present invention are only used to explain the relative positional relationship and movement conditions between components in a specific posture (as shown in the drawings). If this specific posture changes, the directional indications will also change accordingly.

[0035] In the description of the present invention, it should also be noted that unless otherwise clearly defined and limited, the terms "installation", "connection" and "connection" should be understood in a broad sense. For example, it can be a fixed connection, a detachable connection or an integral connection; it can be a mechanical connection or an electrical connection; it can be directly connected or indirectly connected through an intermediate medium, and it can be the internal communication of two components. For those of ordinary skill in the art, the specific meanings of the above terms in the present invention can be understood according to specific situations.

[0036] In addition, the descriptions involving "first", "second", etc. in the present invention are for descriptive purposes only, and should not be construed as indicating or implying their relative importance or implicitly specifying the quantity of the indicated technical features. Thus, the features defined with "first" and "second" may explicitly or implicitly include at least one such feature. The meaning of "and / or" appearing throughout the text is that it includes three parallel solutions. Taking "A and / or B" as an example, it includes solution A, or solution B, or the solution where both A and B are satisfied simultaneously. The technical solutions between various embodiments can be combined with each other, but it must be based on the ability of those of ordinary skill in the art to implement. When the combination of technical solutions results in contradictions or cannot be implemented, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection required by the present invention.

[0037] The present invention provides an optical fiber balloon catheter, which can be applicable to delivering photosensitizers during intravascular stenosis lesions and can also be applicable to other situations where drugs need to be delivered using a balloon, without limitation here.

[0038] Referring to Figures 1 to 4 , in some embodiments of the present invention, the optical fiber balloon catheter includes a catheter body 10, a balloon 20, and a flow buffering component; the balloon 20 is disposed at the distal end of the catheter body 10, and drugs are provided on the surface of the balloon 20; at least during the process of delivering the balloon 20 to the target site, the flow buffering component is located on the impact-receiving side of the balloon 20 facing the fluid impact, and the flow buffering component is used to slow down the scouring of the fluid on the drugs on the surface of the balloon 20 during this process; wherein, when the optical fiber balloon catheter moves reversely relative to the fluid, the impact-receiving side is the distal side of the balloon 20; when the optical fiber balloon catheter moves in the same direction as the fluid, the impact-receiving side is the proximal side of the balloon 20.

[0039] In this embodiment, the flow buffering component can adopt a structure similar to the inflatable structure of the balloon 20 or a structure that can be automatically folded and unfolded, etc., without limitation here. The flow buffering component has a large flow resistance surface after being inflated or unfolded, which can achieve a good effect of slowing down the blood flow scouring and will not completely block the blood vessel Ve to cause danger. The flow buffering component has a small volume when not inflated or folded, which is beneficial to the retraction of the optical fiber balloon catheter and also helps to save the cost of product packaging materials.

[0040] In this embodiment, the drug can be a drug coating applied to the surface of the balloon 20, or drug particles filled in several grooves on the surface of the balloon 20, or drug powder or tablets sandwiched between the folding wings of the balloon 20, etc. The drug may include a photosensitizer to achieve interventional treatment of blood vessel Ve; after the balloon 20 is expanded, the photosensitizer is released to the inner wall of the blood vessel Ve, and light with a specific wavelength (400 - 500 nm) is emitted through the optical fiber 40 to activate the photosensitizer, triggering the formation of covalent cross-links of amino acids on the inner wall of the blood vessel Ve, achieving a supporting effect on the blood vessel Ve, thereby avoiding the problem of blood vessel Ve retraction. Specifically, the photosensitizer can be naphthalimide dimer and its derivatives, which is not limited here.

[0041] In addition, a drug coating for inhibiting restenosis of blood vessel Ve can be provided on the outer surface of the balloon 20. The drug for inhibiting restenosis of blood vessel Ve can be used to treat stenosis and occlusion of blood vessel Ve, which helps to further improve the treatment effect. The drug for inhibiting restenosis of blood vessel Ve can be a macrolide immunosuppressant, a macrolide antibiotic, rapamycin, a structural derivative and functional analogue of rapamycin, everolimus, a structural derivative and functional analogue of everolimus, paclitaxel, taxanes, zotarolimus, sirolimus, biolimus, tacrolimus or temsirolimus or temsirolimus compounds, etc.

[0042] It can be understood that the present invention improves the structure of the optical fiber balloon catheter, slows down the erosion of the fluid on the balloon 20 during the transportation process of the optical fiber balloon catheter, and effectively reduces the loss of the drug on the surface of the balloon 20 during transportation.

[0043] To further enhance the effect of the flow-slowing component in slowing down the erosion of the fluid on the balloon 20, referring to Figures 1 - 4 , in some embodiments, define the dimension of the flow-slowing component in the radial direction of the catheter body 10 when it is in the working state as a, and define the dimension of the balloon 20 in the radial direction of the catheter body 10 when it is in the folded state as b, then the following relational expression is satisfied:

[0044] b ≤ a < c;

[0045] In the formula, c is the inner diameter of the human blood vessel Ve.

[0046] By setting the dimension of the flow retardation member in the radial direction of the catheter body 10 when it is in the working state to be smaller than the inner diameter of the blood vessel Ve, the present invention effectively avoids the long-term blockage of the blood vessel Ve during the transportation of the optical fiber balloon catheter, can effectively avoid the adverse reactions caused by the long-term blockage of the blood vessel Ve, and ensures the safety of the operation. Moreover, by setting the dimension of the flow retardation member in the radial direction of the catheter body 10 when it is in the working state to be greater than or equal to the dimension of the balloon 20 in the radial direction of the catheter body 10 when the balloon 20 is in the folded state, the present invention achieves a better flow retardation effect, thereby avoiding the excessive washing away of the drug on the surface of the balloon 20 by the blood and being lost, and greatly enhancing the treatment effect. It should be noted that for the prior art mentioned in the background art, in the treatment stage, the time for the drug balloon to release the drug is relatively short, and the impact of blocking the blood vessel Ve for a short time on the normal blood circulation of the human body is not significant. Therefore, the solution of blocking the blood vessel Ve by the blocking balloon in the prior art can be applied to this stage. However, the transportation process of the optical fiber balloon catheter takes a long time. If the solution of the prior art is applied to the transportation stage of the optical fiber balloon catheter discussed in the present invention, it will cause the long-term blockage of the blood vessel Ve and the continuous interruption of blood supply, resulting in a series of serious consequences.

[0047] In one embodiment, referring to Figure 1 and Figure 2 , the flow retardation member is the inflatable body 31. The catheter body 10 is provided with a first channel and a second channel both for introducing liquid. The balloon 20 is communicated with the first channel, and the inflatable body 31 is arranged at the distal end of the catheter body 10 and communicated with the second channel.

[0048] As Figure 1 and Figure 2 shown, when the optical fiber balloon catheter is designed to move reversely relative to fluids such as blood during the operation, the inflatable body 31 should be arranged on the distal side of the balloon 20; when the optical fiber balloon catheter is designed to move in the same direction relative to fluids such as blood during the operation, the inflatable body 31 should be arranged on the proximal side of the balloon 20.

[0049] In this embodiment, the projection of the inflatable body 31 in the radial direction of the catheter body 10 can be circular, oval, peanut-shaped, "T"-shaped, umbrella-shaped, conical, etc., which is not limited here.

[0050] During the operation, the balloon 20 and the inflatable body 31 enter the blood vessel Ve under the guidance of a guide wire (the catheter body 10 is provided with a guide wire lumen and a guide wire inlet and a guide wire outlet 50b that are respectively communicated with the guide wire lumen. The guide wire inlet is located at the most distal end of the catheter body 10, and the guide wire outlet 50b is located at the nearest end of the catheter body 10; the specific guiding process is as follows: after the guide wire is positioned, the nearest end of the guide wire exposed outside the body is inserted into the guide wire lumen from the guide wire inlet at the most distal end of the fiber optic balloon catheter and passes out through the guide wire outlet 50b, and then the fiber optic balloon catheter is pushed forward to make the balloon 20 enter the blood vessel Ve). At this time, the balloon 20 is in a folded state, and the fluid reaches the inflatable body 31 from the inflatable body filling port 50d at the proximal end of the catheter body 10 through the filling cavity to make it inflated. After the inflatable body 31 is inflated, its outer diameter is smaller than the outer diameter of the blood vessel Ve. During the transportation process, the inflatable body 31 has the effect of slowing down the blood flow, so that drugs such as photosensitizers on the surface of the balloon 20 will not be lost due to excessive flushing of the blood flow; when the balloon 20 reaches the diseased tissue, the balloon 20 starts to be inflated, and the fluid reaches the balloon 20 from the balloon filling port 50a through the filling cavity of the balloon 20 to inflate the balloon 20, making the balloon 20 contact the diseased tissue, and the photosensitizer reaches the diseased tissue; then, the laser generator is used to control the optical fiber 40 to emit light with a wavelength of 400-500 nm to activate the photosensitizer, thereby triggering the cross-linking of proteins in the wall of the blood vessel Ve to form a natural blood vessel Ve stent, so that the dilated blood vessel Ve can be maintained; finally, the balloon 20 and the inflatable body 31 are depressurized to make them contract and withdrawn from the body.

[0051] In another embodiment, referring to Figure 3 , the flow-slowing component is a foldable structure 32. The catheter body 10 is provided with a third channel for the flow-slowing guide wire 321 to pass through. The third channel has an outlet on the distal side of the balloon 20. The foldable structure 32 is transported to the outside of the outlet of the third channel through the flow-slowing guide wire 321 and automatically unfolds after detaching from the outlet of the third channel. Among them, when the foldable structure 32 is in a folded state, the dimension in the radial direction of the catheter body 10 can be set to be smaller than the dimension of the third channel in the radial direction of the catheter body 10. The present invention adopts the foldable structure 32, which can make the structure of the fiber optic balloon catheter more compact, and each component or assembly can be produced modularly, which is more convenient for production and manufacturing, and the operation during the operation is also relatively simple.

[0052] In this embodiment, the foldable structure 32 can be a metal braided wire basket, a crocheted wire basket, or a metal stent wrapped with a polymer filter membrane wire basket, etc., and is not limited here.

[0053] At the beginning of the procedure, the foldable structure 32 is in a contracted state, and will automatically expand when it is delivered to the distal side of the balloon 20. During the delivery process, the foldable structure 32 has a slowing effect on the blood flow, so that the photosensitizer on the surface of the balloon 20 will not be lost due to excessive flushing of the blood flow. Specifically, when the foldable structure 32 is pushed out from the outlet of the third channel through the slow-flow guide wire 321, it can be automatically expanded; when the drug delivery is completed, when the foldable structure 32 is withdrawn to the outlet position of the third channel, it can be automatically contracted under its obstruction, restored to a folded state, and withdrawn through the third channel.

[0054] During the operation, the balloon 20 enters the blood vessel Ve under the guidance of the guidewire (the catheter body 10 is provided with a guidewire cavity and a guidewire inlet and a guidewire outlet 50b respectively connected to the guidewire cavity, the guidewire inlet is located at the farthest end of the catheter body 10, and the guidewire outlet 50b is located at the nearest end of the catheter body 10; the specific guidance process is: after the guidewire is positioned, the nearest end of the guidewire exposed outside the body is passed through the guidewire inlet at the farthest end of the fiber optic balloon catheter into the guidewire cavity and out of the guidewire outlet 50b, and then the fiber optic balloon catheter is pushed forward to make the balloon 20 enter the blood vessel Ve). At this time, the foldable structure 32 is in a contracted state, and the foldable structure 32 is transported to the distal side of the balloon 20 through the entrance of the third channel (i.e., the foldable structure entrance 50e shown in the figure) through the slow-flow guidewire 321. After leaving the outlet, the foldable structure 32 automatically unfolds. The foldable structure 32 has an effect on blood flow The effect of slowing down the speed prevents the photosensitizer on the surface of the balloon 20 from being lost due to excessive flushing of the blood flow; when the balloon 20 reaches the diseased tissue, the fluid passes through the balloon 20 filling cavity from the balloon filling port 50a to reach the balloon 20, filling the balloon 20, thereby making the balloon 20 contact with the diseased tissue and allowing the photosensitizer to reach the diseased tissue; then, the optical fiber 40 is controlled by an external laser generator to emit light with a wavelength of 400-500nm to activate the photosensitizer, thereby initiating cross-linking of proteins in the wall of the blood vessel Ve, forming a natural blood vessel Ve stent, so that the expanded blood vessel Ve can be maintained; finally, the slow-flow guide wire 321 is pulled back to retract the foldable structure 32, and the foldable structure 32 will automatically fold when it touches the outlet of the third channel until the foldable structure 32 is completely withdrawn from the body; finally, the balloon 20 is depressurized to shrink, and then the balloon 20 is withdrawn from the body.

[0055] In yet another embodiment, referring to Figure 4 The flow-slowing component may also be a structure including a folding frame 331 and a flow-blocking film 332 wrapped on the folding frame 331. The flow-blocking film 332 is provided with a flow-blocking surface on its side facing the fluid impact. The flow-blocking surface may preferably be arc-shaped, so as to achieve the flow-slowing effect while avoiding damage caused by a large impact locally, which helps to improve its service life.

[0056] Similar to the aforementioned inflatable body 31 solution, the flow retardation component formed by the folding frame 331 and the blocking film 332 in this embodiment can select its specific installation position according to the specific application scenario of the optical fiber balloon catheter. When the optical fiber balloon catheter is designed to move reversely relative to fluids such as blood during the operation, the flow retardation component should be installed on the distal side of the balloon 20; when the optical fiber balloon catheter is designed to move in the same direction as fluids such as blood during the operation, the flow retardation component should be installed on the proximal side of the balloon 20.

[0057] In this embodiment, the folding frame 331 can be made of medical shape memory metal or plastic material, and the blocking film 332 can be made of polymer material, etc., without specific limitation.

[0058] It can be understood that the optical fiber balloon catheter of the present invention realizes slowing down the scouring of blood on the balloon 20 during the long-term transportation process by setting the above-mentioned flow retardation component, and at the same time effectively improves the convenience of the transportation operation of the optical fiber balloon catheter and the efficiency of the operation.

[0059] Furthermore, to ensure the smoothness of the optical fiber balloon catheter entering and withdrawing from the blood vessel after the treatment, in this embodiment, a receiving sleeve 333 that can move axially is sleeved on the outer periphery of the catheter body 10 for the release and recovery of the flow retardation component. The receiving sleeve 333 can be switched between a first position and a second position; in the first position, the flow retardation component is integrally folded and received in the receiving sleeve 333. In this state, the overall diameter of the optical fiber balloon catheter is smaller, the withdrawal is more convenient, and the packaging volume is smaller; in the second position, the flow retardation component completely disengages from the receiving sleeve 333, and the folding frame 331 automatically unfolds. In this embodiment, the receiving sleeve 333 can be set as a manual control structure that can be manually pushed and pulled for axial movement, or can be set as an automatic control structure that moves axially by operating the buttons of the operating handle, without limitation here.

[0060] In addition, to activate the photosensitizer during the operation, cause the amino acids on the inner wall of the blood vessel Ve to form covalent crosslinks, and support the blood vessel Ve, thereby avoiding the problem of blood vessel Ve retraction, refer to Figures 1 to 4 In these foregoing embodiments, the catheter body 10 of the optical fiber balloon catheter can be provided with a fourth channel for the optical fiber 40 to pass through. The fourth channel is communicated with the balloon 20. The proximal end of the optical fiber 40 is connected to an external laser generator. The optical fiber 40 enters the fourth channel through the optical fiber inlet 50c, and the distal end of the optical fiber 40 is arranged at the balloon 20.

[0061] For the convenience of connecting a laser generator, guiding the balloon 20 to the lesion site, inflating the balloon 20, inflating the inflatable body 31, guiding the foldable structure 32 to the distal side of the balloon 20, etc., so as to achieve interventional treatment and improve the efficiency of the operation, in this embodiment, the fiber-optic balloon catheter may include a catheter hub 50. The catheter hub 50 is provided at the proximal end of the catheter body 10, and the catheter hub 50 is provided with a plurality of interfaces or inlets that are in one-to-one communication with the inner cavity of the catheter body 10. The number and type of the interfaces or inlets can be determined according to the number and type of the specific cavities of the inner cavity of the catheter body 10 (including but not limited to the above-mentioned first channel, second channel, third channel, and fourth channel), and there is no limitation here.

[0062] The above are only alternative embodiments of the present invention, and do not limit the patent scope of the present invention. Any equivalent structural transformation made under the inventive concept of the present invention by using the content of the specification and drawings of the present invention, or any direct / indirect application in other related technical fields is included in the patent protection scope of the present invention.

Claims

1. An optical fiber balloon catheter, characterized in that, Comprising: A catheter body; A balloon disposed at the distal end of the catheter body, with a drug provided on the surface of the balloon; And A flow retardation member, at least during the process of delivering the balloon to the target site, the flow retardation member is located on the impact-receiving side of the balloon facing the fluid, and the flow retardation member is used to slow down the scouring of the fluid on the drug on the surface of the balloon during this process; The flow retardation member is a foldable structure, and the foldable structure has a flow-blocking surface after unfolding. The catheter body is provided with a third channel for a flow retardation guide wire to pass through, and the third channel has an outlet on the distal side of the balloon. The foldable structure is delivered to the outside of the outlet of the third channel through the flow retardation guide wire and automatically unfolds after detaching from the outlet of the third channel; or, the flow retardation member includes a folding frame and a flow-blocking film covering the folding frame. The flow-blocking film is provided with a flow-blocking surface on its impact-receiving side facing the fluid. A receiving sleeve that is axially movable along the catheter body is sleeved on the outer periphery of the catheter body, and the receiving sleeve is used to release and recover the flow retardation member; Define the size of the flow retardation member in the radial direction of the catheter body when it is in the working state as a, and define the size of the balloon in the radial direction of the catheter body when it is in the folded state as b, and they satisfy the following relationship: b ≤ a < c; In the formula, c is the inner diameter of the human blood vessel; Wherein, when the fiber optic balloon catheter moves reversely relative to the fluid, the impact-receiving side is the distal side of the balloon; When the fiber optic balloon catheter moves in the same direction as the fluid, the impact-receiving side is the proximal side of the balloon.

2. The fiber optic balloon catheter according to claim 1, wherein The foldable structure is a metal braided wire basket, a crocheted wire basket or a metal stent wrapped with a polymer filter membrane wire basket.

3. The fiber optic balloon catheter according to claim 1, wherein, The size of the foldable structure in the radial direction of the catheter body when it is in the folded state is smaller than the size of the third channel in the radial direction of the catheter body.

4. The fiber optic balloon catheter according to claim 1, wherein The catheter body is further provided with a fourth channel for a fiber optic to pass through, and the fourth channel is communicated with the balloon. The proximal end of the fiber optic is connected to an external laser generator; and / or The fiber optic balloon catheter further includes a catheter hub, the catheter hub is disposed at the proximal end of the catheter body, and the catheter hub is provided with a plurality of interfaces or inlets that are in one-to-one communication with the inner cavity of the catheter body.

5. The fiber optic balloon catheter according to claim 4, wherein, The drug includes a photosensitizer, and the photosensitizer is naphthalimide dimer and its derivatives; The drug further includes a drug for inhibiting vascular restenosis, and the drug for inhibiting vascular restenosis is a macrolide immunosuppressant, a macrolide antibiotic or a taxane.

Images